Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 270 entries
View as:

Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02227108 Org: User:
Start: 08/31/14 End: 11/30/15 Due: 11/30/16

Study of MEDI 507 in the Treatment of Pediatric Patients

Phase: N/A Priority: Normal
NCT ID: NCT00813618 Org: User:
Start: 09/30/99 End: 08/31/04 Due: 08/31/05

A Phase 1, Open-label Study to Investigate the Pharmacokinetics of Tralokinumab (CAT-354) in Adolescents With Asthma

Phase: N/A Priority: Normal
NCT ID: NCT01592396 Org: User:
Start: 06/30/12 End: 01/31/13 Due: 01/31/14

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age

Phase: N/A Priority: Normal
NCT ID: NCT00952705 Org: User:
Start: 08/31/09 End: 03/31/10 Due: 03/31/11

Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884

Phase: N/A Priority: Normal
NCT ID: NCT03001297 Org: User:
Start: 01/17/17 End: 08/10/18 Due: 08/10/19

Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children

Phase: N/A Priority: Normal
NCT ID: NCT00345670 Org: User:
Start: 06/30/06 End: 05/31/07 Due: 05/31/08

A Study of the Safety and Tolerability of MEDI-551 in Scleroderma

Phase: N/A Priority: Normal
NCT ID: NCT00946699 Org: User:
Start: 03/31/10 End: 03/31/14 Due: 03/31/15

A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02000947 Org: User:
Start: 10/25/13 End: 09/17/19 Due: 09/17/20

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT01585766 Org: User:
Start: 04/24/12 End: 06/20/16 Due: 06/20/17

A Clinical Study to Assess the Safety of a New Influenza Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT01104493 Org: User:
Start: 05/31/10 End: 12/31/10 Due: 12/31/11

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children

Phase: N/A Priority: Normal
NCT ID: NCT00113490 Org: User:
Start: 05/31/05 End: 02/28/06 Due: 02/28/07

Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of Influenza Virus Vaccine, (CAIV-T) in Healthy Children

Phase: N/A Priority: Normal
NCT ID: NCT00192374 Org: User:
Start: 02/28/02 End: 11/30/02 Due: 11/30/03

Phase I Trial Evaluating Safety and Tolerability of CAIV-T in Healthy Japanese Male Adults

Phase: N/A Priority: Normal
NCT ID: NCT00224783 Org: User:
Start: 08/31/02 End: 09/30/02 Due: 09/30/03

A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants

Phase: N/A Priority: Normal
NCT ID: NCT02290340 Org: User:
Start: 01/13/15 End: 09/28/16 Due: 09/28/17

A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease

Phase: N/A Priority: Normal
NCT ID: NCT01448850 Org: User:
Start: 11/30/11 End: 02/28/14 Due: 02/28/15

A Study to Evaluate the Safety of a Monovalent Vaccine in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT00480155 Org: User:
Start: 05/31/07 End: 12/31/07 Due: 12/31/08

A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years.

Phase: N/A Priority: Normal
NCT ID: NCT00192179 Org: User:
Start: 06/30/03 End: 07/31/03 Due: 07/31/04

A Study to Evaluate Pharmacokinetics, Safety and Tolerability of MEDI0382 in Renal Impairment Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03235375 Org: User:
Start: 10/27/17 End: 04/24/18 Due: 04/24/19

Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season

Phase: N/A Priority: Normal
NCT ID: NCT00316264 Org: User:
Start: 04/30/06 End: 02/28/07 Due: 02/28/08

A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02221960 Org: User:
Start: 09/15/14 End: 07/03/17 Due: 07/03/18

Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT02255760 Org: User:
Start: 09/04/14 End: 04/20/15 Due: 04/20/16

A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02085473 Org: User:
Start: 03/19/14 End: 07/10/14 Due: 07/10/15

A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT01127321 Org: User:
Start: 05/31/10 End: 07/31/12 Due: 07/31/13

Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00066196 Org: User:
Start: 08/31/03 End: 06/30/07 Due: 06/30/08

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

Phase: N/A Priority: Normal
NCT ID: NCT00192309 Org: User:
Start: 09/30/01 End: 12/31/01 Due: 12/31/02